Tirzepatide vs Cagrilintide
Both Tirzepatide and Cagrilintide are used for weight-loss and metabolic. Here's how their evidence, dosing, and regulatory status actually compare.
Tirzepatide
Evidence A+Tirzepatide (Mounjaro / Zepbound)
A dual GIP/GLP-1 receptor agonist that achieved up to 22.5% mean weight loss in the SURMOUNT-1 trial — the highest of any FDA-approved weight loss medication.
View full Tirzepatide profile →Cagrilintide
Evidence ACagrilintide (long-acting amylin analog)
A once-weekly amylin analog that reduces appetite via the area postrema. Combined with semaglutide ('CagriSema') it has produced ~22% weight loss in trial data.
View full Cagrilintide profile →Side-by-Side
| Attribute | Tirzepatide | Cagrilintide |
|---|---|---|
| Evidence Grade | A+ | A |
| FDA Status | FDA-approved for weight management and type 2 diabetes | Not FDA-approved — combined with semaglutide as CagriSema; Phase 3 in progress |
| Typical Dose | 2.5–15 mg weekly (subcutaneous injection) | Trial range: 0.16–4.5 mg weekly (subcutaneous) |
| Clinics Indexed | 1,850 | 8 |
| Categories | weight-loss, metabolic | weight-loss, metabolic |
Key reported benefits — Tirzepatide
- ✓Superior weight loss
- ✓Dual hormone targeting
- ✓Blood sugar control
- ✓Reduced cardiovascular risk
Key reported benefits — Cagrilintide
- ✓Amylin pathway weight loss
- ✓Synergy with GLP-1
- ✓Lower-dose tolerability
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.